Market Cap
$6.1B
BLCO
Bausch & Lomb Corp
$17.11 ▲ +1.00%
Prev close $16.94Market cap$6.1B
ConsensusHold
12-mo target$19.04 (+11.3%)
▲ Bullish
Analyst conviction 6/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)12 New Institutional Positions7 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on BLCO right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Buy (56%)
Inst. Holders
50 funds
Inst. Value
$306.6M
Inst. Activity
12 buys / 7 sells
Insider Activity
$727.3K buy / $1.2M sell
Insider Net $
-$467.0K
Social Sentiment
50° Neutral
SEC Reports
16
Price chart 30d -5.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 Event
Gemini Insurance Company v. Bausch & Lomb Americas, Inc.
Court ruling (del) — Docket: 127, 2026
Aug 25, 2026 clinical_trial_readout
Aug 15, 2026 SEC Results Pending: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination (Phase 2) — Completed 89d ago
Trial: A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease Sp
A cluster of insider selling at Bausch + Lomb, totaling ~$988K, was driven by two directors and an SVP. The largest trad
CLUSTER — Impact 3/10
Robert J. Chersi filed an initial Statement of Beneficial Ownership (Form 3) as a director and/or officer of Bausch + Lo
3 — Impact 2/10
Barbara Trebbi filed a Form 3 initial statement of beneficial ownership on August 14, 2026, reporting no securities owne
3, CLUSTER — Impact 2/10
Aug 12, 2026 Insider
Trebbi Barbara was granted 11,776 shares
Director
Aug 12, 2026 Insider
Chersi Robert J was granted 11,776 shares
Director
Aug 12, 2026 Insider
PAUL LAURENCE E was granted 11,776 shares
Director
Analyst ratings buy % +5.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
56% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 15, 2026 | Needham | REITERATE | Hold | 50% |
| Sep 9, 2026 | Leerink Partners | INITIATE | Outperform | 49% |
| Aug 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 3, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jul 30, 2026 | UBS | MAINTAIN | Buy | 55% |
| Jul 28, 2026 | UBS | INITIATE | Buy | 55% |
| Jul 8, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Jul 6, 2026 | Evercore ISI Group | MAINTAIN | In-Line | 59% |
| Apr 30, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Apr 30, 2026 | Evercore ISI Group | MAINTAIN | In-Line | 59% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 7 | 7 | 1 | 0 | 56% | |
| Aug 1, 2026 | 3 | 7 | 7 | 1 | 0 | 56% | |
| Jul 1, 2026 | 3 | 6 | 8 | 1 | 0 | 50% | |
| Jun 1, 2026 | 3 | 6 | 8 | 1 | 0 | 50% | |
| May 1, 2026 | 3 | 6 | 9 | 1 | 0 | 47% | |
| Apr 1, 2026 | 3 | 6 | 9 | 1 | 0 | 47% | |
| Mar 1, 2026 | 3 | 6 | 9 | 1 | 0 | 47% | |
| Feb 1, 2026 | 3 | 7 | 8 | 1 | 0 | 53% |
Price targets
Where 13 covering analysts think BLCO trades over the next 12 months.
$19.04 +11.3% upside Buy
Current$17.11 Low$16.00 Median$18.50 High$24.00 13 analysts
$16.00$24.00
Analyst rating Buy· 2.3/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 3 bullish, 0 bearish, 1 mixed, 12 neutral · avg impact 3.7/10.
NEUTRALCLUSTER3/10
A cluster of insider selling at Bausch + Lomb, totaling ~$988K, was driven by two directors and an S
Aug 15, 2026
NEUTRAL32/10
Robert J. Chersi filed an initial Statement of Beneficial Ownership (Form 3) as a director and/or of
Aug 14, 2026
NEUTRAL3, CLUSTER2/10
Barbara Trebbi filed a Form 3 initial statement of beneficial ownership on August 14, 2026, reportin
Aug 14, 2026
NEUTRAL32/10
Thomas Appio filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing 27
Aug 14, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
Enforcement
Gemini Insurance Company v. Bausch & Lomb Americas, Inc.
Court ruling (del) — Docket: 127, 2026
Aug 25, 2026
Clinical Trial
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
Phase Phase 2 — COMPLETED
Aug 25, 2026
clinical_trial_readout
Results Pending: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination (Phase 2) — Completed 89d ago
Trial: A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease Sponsor: Bausch & Lomb Incorporated Phase: Phase 2 |
Aug 14, 2026
short_interest_report
Short Interest: BLCO up 5% to 3.2M shares
Settlement 2026-08-14 | Days to cover: 10.22 | ≈0.89% of shares outstanding (est.)
Aug 11, 2026
Clinical Trial
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Phase Phase 2 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.22 | $0.20–$0.26 | 20.5% | +1.6% | 3↑ 4↓ | $1.4B | 13 |
| Next Q | $0.35 | $0.32–$0.39 | 10.3% | +0.9% | 4↑ 2↓ | $1.5B | 13 |
| Current FY | $0.81 | $0.73–$0.86 | 58.5% | +0.5% | 8↑ 2↓ | $5.5B | 13 |
| Next FY | $1.11 | $0.99–$1.30 | 37.2% | +1.5% | 5↑ 3↓ | $5.8B | 13 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.217 | — |
| 7d ago | $0.213 | +0.004 |
| 30d ago | $0.213 | +0.003 |
| 60d ago | $0.218 | -0.001 |
| 90d ago | $0.218 | -0.002 |
Institutional ownership
Which big funds own BLCO (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $306.6M total value (18,517,091 shares) as of 2026-Q2. Top holders: ICAHN, DEUTSCHE, D.. Net buying activity: 12 institutions added/increased vs 7 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ICAHN CARL C | 3,500,000 | $58.0M | 18.9% | — |
| DEUTSCHE BANK AG\ | 3,423,046 | $56.7M | 18.5% | — |
| D. E. Shaw & Co., Inc. | 3,323,021 | $55.0M | 17.9% | — |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,364,980 | $22.6M | 7.4% | ADD +39.0% |
| CITADEL ADVISORS LLC | 987,730 | $16.4M | 5.3% | ADD +40.1% |
| MORGAN STANLEY | 703,348 | $11.6M | 3.8% | — |
| TUDOR INVESTMENT CORP ET AL | 532,030 | $8.8M | 2.9% | ADD +41.3% |
| UBS Group AG | 465,197 | $7.7M | 2.5% | — |
| GOLDMAN SACHS GROUP INC | 420,194 | $7.0M | 2.3% | ADD +43.5% |
| Woodline Partners LP | 386,876 | $6.4M | 2.1% | TRIM -49.9% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | 982,062 | 1,364,980 | +39.0% | $22.6M |
| CITADEL ADVISORS LLC | ADD | 705,221 | 987,730 | +40.1% | $16.4M |
| TUDOR INVESTMENT CORP ET AL | ADD | 376,446 | 532,030 | +41.3% | $8.8M |
| GOLDMAN SACHS GROUP INC | ADD | 292,886 | 420,194 | +43.5% | $7.0M |
| Trexquant Investment LP | DOUBLED | 147,797 | 325,766 | +120.4% | $5.4M |
| NOMURA HOLDINGS INC | NEAR_EXIT | 1,256,181 | 255,977 | -79.6% | $4.2M |
| JANE STREET GROUP, LLC | TRIM | 322,258 | 181,520 | -43.7% | $3.0M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 303,163 | 176,740 | -41.7% | $2.9M |
| Point72 Asset Management, L.P. | TRIM | 283,138 | 175,819 | -37.9% | $2.9M |
| JPMORGAN CHASE & CO | DOUBLED | 150 | 120,689 | +80359.3% | $2.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
19 insiders, 50 transactions. Net -$467.0K — $727.3K bought, $1.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Trebbi Barbara | Director | AWARD | 11,776 | — | — |
| Aug 12, 2026 | Chersi Robert J | Director | AWARD | 11,776 | — | — |
| Aug 12, 2026 | PAUL LAURENCE E | Director | AWARD | 11,776 | — | — |
| Aug 10, 2026 | Munsch Frederick | SVP, Controller and CAO | SELL | 52,900 | $16.78 | $887.7K |
| Aug 7, 2026 | VON ESCHENBACH ANDREW C. | Director | SELL | 6,059 | $16.58 | $100.5K |
| Aug 6, 2026 | VON ESCHENBACH ANDREW C. | Director | SELL | 12,500 | $16.50 | $206.3K |
| Aug 5, 2026 | SAUNDERS BRENT L | Chairman of the Board and CEO | TAX W/H | 4,231 | $16.76 | $70.9K |
| Aug 5, 2026 | SAUNDERS BRENT L | Chairman of the Board and CEO | AWARD | 281,879 | — | — |
| Aug 5, 2026 | Eldessouky Sam | EVP and CFO | AWARD | 50,335 | — | — |
| Aug 5, 2026 | Stewart Andrew J. | President, GPIC | AWARD | 16,778 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BLCO.
Shares short
3,164,899
Settlement Sep 15, 2026
Change vs prior
-7.1%
Semi-monthly cycle
Days to cover
7.8
At avg daily volume
Of shares outstanding
≈0.9%
Estimate — not % of float
All BLCO filing & press-release reports (16)
- CLUSTER reportAug 15, 2026
- 3 reportAug 14, 2026
- 3, CLUSTER reportAug 14, 2026
- 3 reportAug 14, 2026
- CLUSTER reportAug 12, 2026
- 144 reportAug 7, 2026
- 144 reportAug 6, 2026
- 8-K reportAug 6, 2026
- 8-K reportJul 29, 2026
- CLUSTER reportMar 10, 2026
- CLUSTER reportMar 4, 2026
- CLUSTER reportMar 3, 2026
- CLUSTER reportMar 2, 2026
- CLUSTER reportFeb 27, 2026
- CLUSTER reportFeb 26, 2026
- CLUSTER reportFeb 24, 2026